Tyrosine kinase fusion genes in chronic myeloproliferative diseases

[1]  A. Reiter,et al.  The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1 , 2002, Acta Haematologica.

[2]  N. Cross,et al.  Myeloproliferative Disorders with Translocations of Chromosome 5q31–35: Role of the Platelet-Derived Growth Factor Receptor Beta , 2002, Acta Haematologica.

[3]  J. Melo,et al.  The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. , 2001, Blood.

[4]  R. V. van Etten,et al.  Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling , 2001, The EMBO journal.

[5]  J. Borg,et al.  8p12 Stem Cell Myeloproliferative Disorder: the FOP-Fibroblast Growth Factor Receptor 1 Fusion Protein of the t(6;8) Translocation Induces Cell Survival Mediated by Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt/mTOR Pathways , 2001, Molecular and Cellular Biology.

[6]  M. Tomasson,et al.  The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. , 2001, Blood.

[7]  B Johansson,et al.  Fusion of the BCR and the fibroblast growth factor receptor‐1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: The first fusion gene involving BCR but not ABL , 2001, Genes, chromosomes & cancer.

[8]  M. K. Magnússon,et al.  Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. , 2001, Blood.

[9]  G. Martinelli,et al.  Identification of four new translocations involving FGFR1 in myeloid disorders , 2001, Genes, chromosomes & cancer.

[10]  B. Druker,et al.  Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.

[11]  C. Barthe,et al.  Roots of clinical resistance to STI-571 cancer therapy. , 2001, Science.

[12]  A. Chase,et al.  Cytogenetics of chronic myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[13]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[14]  J. Kutok,et al.  H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). , 2001, Blood.

[15]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[16]  G. Daley,et al.  Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. , 2001, Blood.

[17]  W. R. Bishop,et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. , 2001, Blood.

[18]  Soo-Young Yoon,et al.  Cellular Distribution of Platelet-Derived Growth Factor, Transforming Growth Factor-β, Basic Fibroblast Growth Factor, and Their Receptors in Normal Bone Marrow , 2001, Acta Haematologica.

[19]  M. Tanimoto,et al.  Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). , 2001, Blood.

[20]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[21]  D. Birnbaum,et al.  The 8p12 myeloproliferative disorder. t(8;19)(p12;q13.3): a novel translocation involving the FGFR1 gene , 2000 .

[22]  D. Birnbaum,et al.  The 8p12 myeloproliferative disorder. t(8;19)(p12;q13.3): a novel translocation involving the FGFR1 gene. , 2000, British journal of haematology.

[23]  S. Kulkarni,et al.  Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). , 2000, Cancer research.

[24]  M. Carroll,et al.  TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. , 2000, Experimental hematology.

[25]  D. Birnbaum,et al.  FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). , 2000, Blood.

[26]  J. Aster,et al.  Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. , 2000, The Journal of clinical investigation.

[27]  Y. Kwong,et al.  Chronic myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98/HOXA9 fusion. , 1999, Cancer genetics and cytogenetics.

[28]  D. Smedley,et al.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. , 1999, Neoplasia.

[29]  D. Birnbaum,et al.  Characterization of FIM-FGFR1, the Fusion Product of the Myeloproliferative Disorder-associated t(8;13) Translocation* , 1999, The Journal of Biological Chemistry.

[30]  Tony Hunter,et al.  Receptor signaling: When dimerization is not enough , 1999, Current Biology.

[31]  D. Gilliland,et al.  Transforming Properties of the Huntingtin Interacting Protein 1/ Platelet-derived Growth Factor β Receptor Fusion Protein* , 1999, The Journal of Biological Chemistry.

[32]  Jonathan A. Cooper,et al.  STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation , 1999, Oncogene.

[33]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[34]  D. Birnbaum,et al.  The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. , 1999, Blood.

[35]  J. Aster,et al.  Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes , 1998, The EMBO journal.

[36]  R. Aguiar,et al.  Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. , 1998, Blood.

[37]  C. Heldin,et al.  Signal transduction via platelet-derived growth factor receptors. , 1998, Biochimica et biophysica acta.

[38]  R. Berger,et al.  Fusion of Huntingtin Interacting Protein 1 to Platelet-Derived Growth Factor β Receptor (PDGFβR) in Chronic Myelomonocytic Leukemia With t(5;7)(q33;q11.2) , 1998 .

[39]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Smedley,et al.  The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. , 1998, Human molecular genetics.

[41]  M. Tanimoto,et al.  Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. , 1997, Blood.

[42]  M. Höglund,et al.  BCR/ABL‐negative chronic myeloid leukemia with ETV6/ABL fusion , 1997, Genes, chromosomes & cancer.

[43]  P. Marynen,et al.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.

[44]  S. Hubbard,et al.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.

[45]  T. Golub,et al.  The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways , 1996 .

[46]  J. Melo,et al.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.

[47]  Keisuke Toyama,et al.  The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP96 and class I homeoprotein HOXA9 , 1996, Nature Genetics.

[48]  A. Feinberg,et al.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia , 1996, Nature Genetics.

[49]  R. Aguiar,et al.  A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. , 1995, Leukemia.

[50]  J. Aster,et al.  A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. , 1995, Blood.

[51]  I. Mason.  The ins and outs of fibroblast growth factors , 1994, Cell.

[52]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[53]  J. Wang,et al.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins , 1993, Molecular and cellular biology.

[54]  A. Hagemeijer,et al.  The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features , 1992 .

[55]  C. Fonatsch,et al.  Cytogenetic peculiarities in chronic myelogenous leukemia. , 1990, Cancer genetics and cytogenetics.

[56]  T. Ganesan,et al.  Haematological classification of the chronic myeloid leukaemias. , 1987, Bailliere's clinical haematology.

[57]  K. Ohyashiki,et al.  Ph-negative chronic myelocytic leukemia with a complex translocation involving chromosomes 7 and 11. , 1986, Cancer genetics and cytogenetics.

[58]  R. Kurzrock,et al.  BCR Rearrangement-Ne gative C hronic M yelogenous Leukemia R evisited , 2001 .

[59]  C. Bloomfield,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  T. Hudson,et al.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome , 1998, Nature Genetics.

[61]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Berger,et al.  Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). , 1998, Blood.

[63]  T. Golub,et al.  The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. , 1996, Proceedings of the National Academy of Sciences of the United States of America.